Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial PharmaTimesBoehringer Ingelheim reports significant reductions in weightMetabolic & GLP-1Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) PharmaTimes Boehringer Ingelheim reports significant reductions in weight Metabolic & GLP-1 Read full story Post navigation Previous: Avalyn, in pursuit of better lung drugs, banks $300M in an IPONext: Ray Therapeutics receives EMA PRIME status for gene therapy Related Stories Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints pharminent April 30, 2026 Clinical Data Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3 pharminent April 28, 2026 Clinical Data AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer pharminent April 28, 2026